Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agentAnne-Julie Cloux, Aimable Nahimana, Michele Cea et al.|Oncotarget|2019Cited by 22
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemiaOussama ElMokh, Michel A. Duchosal, Saki Matsumoto et al.|Cell Death and Disease|2022Cited by 16
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myelomaDebora Soncini, Michele Cea, Pamela Becherini et al.|Blood Advances|2024Cited by 5